Abstract 16715: Magnetic Resonance Imaging Based Arterial Signal Enhancement is Associated With Markers of Peripheral Artery Disease
Introduction: Peripheral artery disease (PAD) is associated with impaired lower extremity (LE) function. Contrast-enhanced magnetic resonance imaging (CE-MRI) may quantitatively measure first-pass perfusion of the major lower leg arteries (posterior tibialis [PT], anterior tibialis [AT], peroneal artery [PE]).
Hypothesis: We hypothesized that CE-MRI-based arterial signal enhancement (SE) is associated with markers of PAD.
Methods: A total of 57 individuals (37 PAD, 20 controls) underwent 3.0T CE-MRI. Imaging was performed post reactive hyperemia using bilateral thigh blood-pressure cuffs. First pass-perfusion images were acquired at mid-calf with a high resolution saturation recovery gradient echo pulse sequence. First-pass arterial SE was measured for the PT, AT, and PE. Cross-sectional leg muscle area (CSLMA), exercise ankle brachial index (ABI), and peak walking time (PWT) were measured.
Results: Intraclass correlation (ICC) coefficients were excellent for inter and intra-observer variability of arterial (n=10: 0.948 (95%-confidence interval [CI]: 0.936-0.956), n=9: 1.0 (CI: 1.0-1.0) and CSLMA tracings (n=20: 0.906 (CI: 0.616-0.967), n=20: 0.989 (CI: 0.971-0.996). PAD patients had a lower minimum arterial SE compared to controls (p=0.003, Table). Conversely, maximum arterial SE was higher in controls compared to PAD patients (p=0.0498). Minimum arterial SE was correlated with rest and exercise ABIs (r=0.329, p=0.013; r=0.389, p=0.003). CSLMA showed a stronger association with maximum arterial SE (r=0.349, p=0.008) than with minimum arterial SE (r=0.246, p=0.065). There was a trend toward lower CSLMA in PADs compared to controls (p=0.053). As expected, PWT was reduced in PAD patients compared to controls (p=0.0028) and post exercise ABIs decreased in PAD patients (-0.183, p<0.0001) but not in controls (0.02, p=0.50).
Conclusions: CE-MRI-based first-pass arterial perfusion is impaired in PAD and associated with measures of leg ischemia.
Author Disclosures: J. Holbrook: None. T. Belousova: None. C.M. Short: None. A.A. Taylor: None. V. Nambi: None. J.D. Morrisett: None. C.M. Ballantyne: Consultant/Advisory Board; Modest; Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Novartis, Regeneron, Roche Diagnostic. Research Grant; Significant; NIH, AHA, ADA. Other Research Support; Significant; Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo. Consultant/Advisory Board; Significant; Astra Zeneca, Merck, Pfizer, Sanofi-Synthelabo. J. Bismuth: None. D.J. Shah: None. G. Brunner: None.
- © 2016 by American Heart Association, Inc.